1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > 2015 Strategies in the UK Tumor Marker Testing Market

2015 Strategies in the UK Tumor Marker Testing Market

  • May 2015
  • -
  • Venture Planning Group
  • -
  • 575 pages

Highlights

Comprehensive 575-page analysis of the UK tumor marker testing market.

Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Five-year test volume and sales forecasts over for 40 tumor marker performed in UK hospitals, commercial laboratories and physician offices.

Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 575 pages and 85 tables.

Table Of Contents

2015 Strategies in the UK Tumor Marker Testing Market
Table of Contents


I. Introduction
II. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
G. Personal Testing
III. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Sales and Market Shares
X. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
XI. Design Criteria for Decentralized Testing Products
XII. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
XIII. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
XIV. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Pharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Epigenomics
- Enterix
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila
XV. Appendixes: Appendix I: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications
Appendix II: Assumed Currency Exchange Rates


List of Tables


Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.K., Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
U.K., Estimated Cancer Death Rates
Per 100,000 Population
U.K., Laboratories Performing Tumor
Marker Tests by Market Segment
U.K., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories
Performing Tumor Marker Tests by
Annual Test Volume
U.K., Total Tumor Marker Testing VolumeForecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major
Tumor Marker Test Volume Forecast By Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major
Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics SalesForecast by Market Segment
U.K., AFP Test Volume and Diagnostics SalesForecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., CEA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume
And Diagnostics Sales by Market
Segment
U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market
Segment
U.K., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Total Tumor Marker Sales and
Market Shares Forecast
U.K., CEA Testing Market Diagnostics
Sales by Major Supplier
U.K., PSA Testing Market Diagnostics
Sales by Major Supplier

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review,  Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.